| LDR | | 01675nmm uu200421 4500 |
| 001 | | 000000333696 |
| 005 | | 20240805173530 |
| 008 | | 181129s2018 |||||||||||||||||c||eng d |
| 020 | |
▼a 9780438267589 |
| 035 | |
▼a (MiAaPQ)AAI10829964 |
| 035 | |
▼a (MiAaPQ)mayo:10499 |
| 040 | |
▼a MiAaPQ
▼c MiAaPQ
▼d 248032 |
| 082 | 0 |
▼a 615 |
| 100 | 1 |
▼a Ly, Reynold. |
| 245 | 10 |
▼a Metformin Pharmacogenomics: Functional Genomics of CDC25b and TPD54 Regulation of Metformin Anticancer Response in Breast Cancer. |
| 260 | |
▼a [S.l.] :
▼b College of Medicine - Mayo Clinic.,
▼c 2018 |
| 260 | 1 |
▼a Ann Arbor :
▼b ProQuest Dissertations & Theses,
▼c 2018 |
| 300 | |
▼a 250 p. |
| 500 | |
▼a Source: Dissertation Abstracts International, Volume: 79-12(E), Section: B. |
| 500 | |
▼a Adviser: Liewei Wang. |
| 502 | 1 |
▼a Thesis (Ph.D.)--College of Medicine - Mayo Clinic, 2018. |
| 520 | |
▼a Metformin, a type II diabetic drug, is a promising agent in the treatment of cancer. However, the molecular mechanism of anticancer action is not fully understood. In this thesis, we will describe the pharmacogenomics approach used to identify g |
| 590 | |
▼a School code: 1542. |
| 650 | 4 |
▼a Pharmacology. |
| 650 | 4 |
▼a Oncology. |
| 650 | 4 |
▼a Genetics. |
| 690 | |
▼a 0419 |
| 690 | |
▼a 0992 |
| 690 | |
▼a 0369 |
| 710 | 20 |
▼a College of Medicine - Mayo Clinic.
▼b Molecular Pharmacology and Experimental Therapeutics. |
| 773 | 0 |
▼t Dissertation Abstracts International
▼g 79-12B(E). |
| 773 | |
▼t Dissertation Abstract International |
| 790 | |
▼a 1542 |
| 791 | |
▼a Ph.D. |
| 792 | |
▼a 2018 |
| 793 | |
▼a English |
| 856 | 40 |
▼u http://www.riss.kr/pdu/ddodLink.do?id=T14999374
▼n KERIS |
| 980 | |
▼a 201812
▼f 2019 |
| 990 | |
▼a 관리자 |